Home > Newsletters > Drug Industry Daily > Eyeing COPD Market Boom, GSK, Theravance Plan Late 2012 Filing for Combo Drug
Drug Industry Daily
July 3, 2012 | Vol. 11 No. 130
Eyeing COPD Market Boom, GSK, Theravance Plan Late 2012 Filing for Combo Drug
GlaxoSmithKline (GSK) and Theravance plan late 2012 regulatory filings for their new chronic obstructive pulmonary disease (COPD) candidate, saying initial Phase III data supports their plans to chip away at the $5 billion market share dominated by Boehringer Ingelheim’s Spiriva.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.